Abata Therapeutics

Associate Director / Director, Biostatistics

Remote

Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

Candidates must possess a Ph.D. or M.S. in Biostatistics, Statistics, or a related field, with prior experience in the Biotech/Pharma Industry or a CRO. Required experience includes leading statistical activities for clinical trials across multiple phases, expertise in clinical trial methodology, adaptive designs, and regulatory guidance. Proficiency in SAS, including data simulation and analysis, familiarity with CDISC standards (SDTM/ADaM), and experience with regulatory submissions (NDA/BLA/MAA) are essential. Strong communication and interpersonal skills to explain statistical concepts to non-statisticians, and the ability to work independently in a fast-paced environment are also required.

Responsibilities

The Associate Director / Director, Biostatistics will serve as the lead biostatistician for clinical programs or trials from Phase I through Phase III. Responsibilities include providing strategic input into clinical development plans, study designs, and statistical methodologies, and presenting statistical aspects to internal stakeholders. They will develop or review statistical sections of clinical trial protocols, SAPs, and other key documents. The role involves collaborating with internal teams and CROs to oversee statistical programming, analysis, and validation, and interpreting/communicating statistical results to clinical and regulatory stakeholders. Additionally, they will contribute to regulatory submissions, attend meetings with regulatory agencies, ensure statistical deliverables comply with regulatory requirements, identify process improvements, implement innovative statistical solutions, and represent Biostatistics in cross-functional project teams.

Skills

Biostatistics
Clinical Trials
Statistical Analysis
Study Design
Regulatory Affairs
Data Management
Medical Writing
Leadership

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI